<HashMap><database>iProX</database><scores/><additional><omics_type>Proteomics</omics_type><submitter>Hui Peng</submitter><species>Rattus Norvegicus</species><full_dataset_link>http://www.iprox.org/page/project.html?id=IPX0017356000</full_dataset_link><submitter_email>pengh9@sina.com</submitter_email><submitter_affiliation>First Affiliated Hospital of Chongqing Medical University</submitter_affiliation><sample_protocol></sample_protocol><repository>iProX</repository><data_protocol></data_protocol></additional><is_claimable>false</is_claimable><name>High glucose-induced mitochondrial fission promotes Müller cell activation via suppression of the Hippo pathway</name><description>Diabetic retinopathy (DR) is the leading cause of blindness in diabetic patients, in which high glucose (HG)-induced Müller cell activation constitutes a central pathological event. This study aimed to untangle the critical role and mechanism of mitochondrial fission in this process. We found that under HG conditions, the level of p-Drp1 was significantly elevated (P&lt;0.05), driving excessive mitochondrial fission. Functional experiments confirmed that artificially enhancing mitochondrial fission directly inhibited the Hippo signaling pathway (levels of core proteins p-MST1/2, p-LATS1, and p-YAP decreased, P&lt;0.05, and YAP translocated to the nucleus), thereby activating Müller cells (expression of marker proteins GS and Kir4.1 decreased, while expression of GFAP, AQP4, and inflammatory mediators IL-1β, IL-6, VEGF increased, P&lt;0.05). Key rescue experiments demonstrated that Drp1 silencing (reduced p-Drp1 level, P&lt;0.05) reversed the aforementioned activation; however, co-administration of the Hippo pathway inhibitor XMU-MP-1 re-induced cell activation, proving that the Hippo pathway is a necessary downstream mediator of mitochondrial fission. In a diabetic rat model, elevated p-Drp1, Hippo pathway inhibition, and cell activation were similarly observed; the mitochondrial fission inhibitor Mdivi-1 alleviated this pathological process, whereas XMU-MP-1 counteracted its protective effects. This study systematically elucidates, from ex vivo to in vivo, the causal regulatory axis of "HG- mitochondrial fission- Hippo pathway inhibition—Müller cell activation," providing experimental evidence and a potential target for developing DR-targeted therapeutic strategies centered on intervening in mitochondrial dynamics.</description><dates><publication>Sat May 23 00:00:00 BST 2026</publication></dates><accession>PXD078791</accession><cross_references><TAXONOMY>10116</TAXONOMY></cross_references></HashMap>